Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

69.75EUR
9 Dec 2016
Change (% chg)

€1.50 (+2.20%)
Prev Close
€68.25
Open
€68.43
Day's High
€69.75
Day's Low
€68.36
Volume
59,200
Avg. Vol
33,816
52-wk High
€69.75
52-wk Low
€38.69

DBV.PA

Chart for DBV.PA

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.73
Market Cap(Mil.): €1,681.24
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 29.73 30.40
EPS (TTM): -3.58 -- --
ROI: -38.42 15.87 15.24
ROE: -40.21 16.99 16.58

BRIEF-DBV Technologies announces positive safety data for First Cohort of Phase I study with Viaskin rPT

* Announces positive safety data for First Cohort of Phase I study with Viaskin rPT, a patch booster to address pertussis Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 17 2016

BRIEF-DBV Technologies completes enrollment of phase II study of Viaskin Milk

* DBV Technologies completes enrollment of phase II study of Viaskin Milk for the treatment of milk allergic patients Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 08 2016

BRIEF-DBV Technologies cash position at Sept. 30 down at 277.6 mln euros

* Cash and cash equivalents as of Sept 30 amounted to 277.6 million euros ($308.6 million) compared to 323.4 million euros as of Dec 31, 2015 Source text for Eikon: Further company coverage: ($1 = 0.8994 euros) (Gdynia Newsroom)

Nov 03 2016

BRIEF-DBV Technologies provides topline results from two-year follow-up study

* Topline results from two-year follow-up study of Viaskin Peanut show long-lasting and high levels of desensitization to peanut

Oct 24 2016

Factbox: Nestle Health Science key investments

Nestle believes its Health Science unit will eventually generate annual sales of 10 billion Swiss francs ($10.3 billion). It already has sales of more than 2 billion francs.

Sep 30 2016

BRIEF-DBV Technologies says FDA gives fast track status to Viaskin Milk

* Results of phase I/II clinical study of Viaskin Milk should be presented in H2 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Sep 21 2016

BRIEF-DBV Technologies starts Phase I study of Viaskin rPT for pertussis booster vaccination

* DBV Technologies, Bionet-Asia and the Geneva University Hospitals initiate Phase I study of Viaskin rPT for pertussis booster vaccination Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Sep 06 2016

BRIEF-DBV Technologies announces expansion of clinical program for the treatment of peanut allergy

* Announced on Monday expansion of clinical program Viaskin Peanut for the treatment of peanut allergy

Aug 02 2016

BRIEF-DBV Technologies H1 net loss widens to 49.4 million euros

* H1 net loss of 49.4 million euros ($54.66 million) versus loss of 14.5 million euros year ago

Jul 28 2016

BRIEF-DBV Technologies Sa files for stock shelf with U.S. SEC size undisclosed - SEC Filing

* Says files for stock shelf with U.S. SEC; size undisclosed - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 27 2016

Earnings vs. Estimates